Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(18):2571-2628.
doi: 10.2174/0929867331666230727102016.

Recent Advances in Research on Active Compounds Against Hepatic Fibrosis

Affiliations
Review

Recent Advances in Research on Active Compounds Against Hepatic Fibrosis

Chuang Liu et al. Curr Med Chem. 2024.

Abstract

Background: Almost all chronic liver diseases cause fibrosis, which can lead to cirrhosis and eventually liver cancer. Liver fibrosis is now considered to be a reversible pathophysiological process and suppression of fibrosis is necessary to prevent liver cancer. At present, no specific drugs have been found that have hepatic anti-fibrotic activity.

Objective: The research progress of anti-hepatic fibrosis compounds in recent ten years was reviewed to provide a reference for the design and development of anti-hepatic fibrosis drugs.

Methods: According to the structure of the compounds, they are divided into monocyclic compounds, fused-heterocyclic compounds, and acyclic compounds.

Results: In this article, the natural products and synthetic compounds with anti-fibrotic activity in recent ten years were reviewed, with emphasis on their pharmacological activity and structure-activity relationship (SAR).

Conclusion: Most of these compounds are natural active products and their derivatives, and there are few researches on synthetic compounds and SAR studies on natural product.

Keywords: HSC; Liver fibrosis; SAR; chronic liver diseases; cirrhosis; collagen I..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sarin S.K.; Kumar M.; Eslam M.; George J.; Al Mahtab M.; Akbar S.M.F.; Jia J.; Tian Q.; Aggarwal R.; Muljono D.H.; Omata M.; Ooka Y.; Han K.H.; Lee H.W.; Jafri W.; Butt A.S.; Chong C.H.; Lim S.G.; Pwu R.F.; Chen D.S.; Liver diseases in the Asia-Pacific region: A lancet gastroenterology and hepatology commission. Lancet Gastroenterol Hepatol 2020,5(2),167-228 - DOI - PubMed
    1. Shan L.; Lium Z.; Ci L.; Shuai C.; Lv X.; Li J.; Research progress on the anti-hepatic fibrosis action and mechanism of natural products. Int Immunopharmacol 2019,75,105765 - DOI - PubMed
    1. Li J.; Feng W.; Dai R.; Li B.; Rational design, synthesis and activities of phenanthrene derivatives against hepatic fibrosis. Fitoterapia 2022,159,105176 - DOI - PubMed
    1. Ebrahimi M.; Seyedi S.A.; Nabipoorashrafi S.A.; Rabizadeh S.; Sarzaeim M.; Yadegar A.; Mohammadi F.; Bahri R.A.; Pakravan P.; Shafiekhani P.; Nakhjavani M.; Esteghamati A.; Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Lipids Health Dis 2023,22(1),41 - DOI - PubMed
    1. Wallace S.J.; Tacke F.; Schwabe R.F.; Henderson N.C.; Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports 2022,4(8),100524 - DOI - PubMed

MeSH terms